Evaluating Latest Evidence and Treatment Targets in Moderate to Severe Atopic Dermatitis

Christopher Bunick, MD, PhD, advises on when to consider systemic treatments and the frequency of moving to advanced treatments for patients with moderate to severe atopic dermatitis.

An atopic dermatitis expert discusses the primary and secondary efficacy endpoints and treatment goals commonly assessed in clinical trials for moderate to severe atopic dermatitis.

Christopher Bunick, MD, PhD, examines patient satisfaction upon achieving primary study endpoints in clinical trials and highlights the significance of patient-reported outcomes (PROs) in both clinical trial designs and patient care.

An atopic dermatitis expert describes the results of the Level Up study, a phase 3b/4 trial comparing upadacitinib and dupilumab, which were recently presented at RAD 2024, focusing on the primary and secondary outcomes of the study.

Christopher Bunick, MD, PhD, offers advice for clinicians treating patients with atopic dermatitis.